Rubius Therapeutics, Inc. Gains 45.06%
Wed, Dec 28, 2022 at 07:05 PM
Rubius Therapeutics, Inc. (RUBY:NASDAQ) shot up at $0.24, representing a gain of 45.1%. On Wed, Dec 28, 2022, RUBY:NASDAQ hit a New 2-Week High of $0.24. From Wed, Dec 14, 2022, the stock recorded 55.56% Up Days and 30.00% Green Days
The stock spiked on Wed, Dec 28, 2022 at $0.42 with a volume of 18M+.
About Rubius Therapeutics, Inc. (RUBY:NASDAQ)
Rubius Therapeutics Inc develops red cell therapeutics (RCTs) for the treatment of patients with rare diseases, cancer, and autoimmune diseases.
Top 10 Gainers:
- Kala Pharmaceuticals, Inc. (KALA:NASDAQ), 218.37%
- Minerva Surgical Inc. (UTRS:NASDAQ), 66.15%
- TransCode Therapeutics Inc. (RNAZ:NASDAQ), 51.82%
- Rubius Therapeutics, Inc. (RUBY:NASDAQ), 45.06%
- Hoth Therapeutics, Inc. (HOTH:NASDAQ), 44.74%
- Gorilla Technology Group Inc. (GRRR:NASDAQ), 42.98%
- Nuwellis Inc. (NUWE:NASDAQ), 37.48%
- Argo Blockchain plc (ARBK:NASDAQ), 36.29%
- Unico American Corporation (UNAM:NASDAQ), 35.96%
- Jounce Therapeutics, Inc. (JNCE:NASDAQ), 33.79%